Investor Contact
For investor related questions, please email
investors@aclaristx.com

Press Releases

Press Releases

August 27, 2021
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
August 26, 2021
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
August 5, 2021
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
July 8, 2021
Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
June 9, 2021
Aclaris Announces Pricing of Public Offering of Common Stock
June 8, 2021
Aclaris Announces Proposed Public Offering of Common Stock
June 8, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
May 17, 2021
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 7, 2021
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
March 15, 2021
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
February 25, 2021
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
February 22, 2021
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
February 10, 2021
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
January 20, 2021
Aclaris Announces Pricing of Public Offering of Common Stock
January 19, 2021
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Load More »